Answers are grounded in this paper and cite their sources.
Reveals effective theranostic strategies for managing rare renal metastases in GEP-NET.
A 62-year-old female, a known case of gastroentero-pancreatic neuroendocrine tumours (GEP-NET) with renal metastasis, who underwent somatostatin receptor (SSTR) targeted PET/CT with 18 F-NOTANOC, revealed intense SSTR expression in both primary and metastatic renal lesions. Thereafter, the patient underwent peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE, post-therapy scan of which showed substantial radiopharmaceutical uptake in the corresponding lesions, highlighting theranostic concordance. Renal metastases from GEP-NET are extremely rare but can occur, often presenting as secondary renal lesions with SSTR-targeted imaging playing a vital role, both for diagnosis and treatment with PRRT, as shown in this patient.
No takes yet. Share an insight, caveat, or question.
Bagasariya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: